ArticleFrontiers in oncology2026
Dynamic neutrophil-to-lymphocyte ratio predicts prognosis in patients with soft tissue sarcoma: a retrospective study of 231 cases.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Soft tissue sarcomas (STS) exhibit significant heterogeneity and are classified as rare tumors with a high risk of metastasis. The neutrophil-to-lymphocyte ratio (NLR), a hematological marker indicative of systemic inflammation, has gained broad recognition for its prognostic utility in oncology. This ratio can be used to evaluate the dynamic changes in inflammatory markers during the diagnosis and treatment of tumors. The value of NLR fluctuations in STS has yet to be fully investigated. Methods: This investigation involved a retrospective cohort of 231 patients with STS, all definitively diagnosed and managed at the Musculoskeletal Tumor Center of The First Affiliated Hospital of Zhengzhou University, aiming to evaluate their clinical profiles. The research focused on analyzing the impact of both baseline NLR and its dynamic changes throughout therapy on the prognostic outcomes in STS, with the aim of constructing a nomogram based on delta-NLR. Results: The study cohort comprised 231 individuals diagnosed with STS. Based on delta-NLR trends, participants were categorized into two cohorts: an NLR increase group (n=94) and an NLR decrease group (n=137). Analysis using time-dependent receiver operating characteristic (ROC) curves revealed that delta-NLR possessed greater predictive accuracy for prognosis relative to other hematologic parameters and clinical characteristics. Both univariate and multivariate analyses determined that Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grade, patient age, and delta-NLR served as independent predictors of prognosis. A prognostic nomogram was subsequently constructed integrating these significant factors. The nomogram achieved a C-index of 0.702, and calibration curves verified its accuracy in predicting three- and five-year overall survival (OS) for STS patients. Results from decision curve analysis (DCA) and clinical impact curve assessment additionally validated that utilizing this delta-NLR-based nomogram may offer substantial clinical utility in the management of STS. Conclusion: NLR is valuable for continuous monitoring, and ongoing assessment of NLR provides better survival predictions for patients with STS than using baseline NLR alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.